Sermorelin and tesamorelin often come up together in clinics that offer growth hormone therapies. They sound alike and work in a similar way. But they are not interchangeable, and their status with the FDA is quite different.
How they work
Both are man-made versions of growth hormone-releasing hormone, or GHRH. GHRH is the signal your brain sends to your pituitary gland to release growth hormone. Instead of giving growth hormone directly, these peptides prompt your body to make more of its own.
That is different from somatropin, which is growth hormone itself. Somatropin is a prescription biologic.
Here is how the two compare at a glance.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Approved product today | None in the U.S. | Yes, Egrifta |
| Past or current approved use | Was approved as Geref for children with growth hormone deficiency, and as a diagnostic test | Reduce excess belly fat in adults with HIV and lipodystrophy |
| How people get it now | Prepared by compounding pharmacies on prescription | Prescription brand-name drug |
| FDA review of the product you receive | No, compounded drugs aren’t FDA-approved | Yes, reviewed for safety, effectiveness and quality |
Sermorelin’s history
Sermorelin was once sold under the brand name Geref. The maker discontinued it in 2008. The FDA later determined that it was not withdrawn for reasons of safety or effectiveness. Today, compounding pharmacies prepare sermorelin when a clinician writes a prescription.
Because compounded drugs are not FDA-approved, the FDA does not review each product for quality before you get it. The strength and purity depend on the pharmacy. Clinics may promote sermorelin for energy, body composition or aging, but those uses were never part of its approval.
What to know about tesamorelin
Tesamorelin is sold as Egrifta. It is approved for one specific use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. The label says it is not meant for weight loss.
Its label lists real risks. These include a higher chance of glucose intolerance or diabetes, fluid retention, joint pain, injection-site reactions and allergic reactions. It also raises IGF-1, a hormone linked to growth, and the label advises monitoring it. Tesamorelin should not be used during pregnancy.
Because sermorelin works in a similar way, it is reasonable to ask your clinician whether similar risks could apply.
Questions to ask your clinician
- What condition are you treating, and is this drug approved for it?
- If it is compounded, which pharmacy makes it, and how is quality checked?
- What tests will we do before and during treatment, such as blood sugar or IGF-1?
- How will we know if it is working, and when would we stop?
The bottom line
Sermorelin and tesamorelin share a mechanism but little else. Tesamorelin is an approved drug for a narrow medical use. Sermorelin is a compounded product without a current approved version. Neither is approved to slow aging. A clinician and pharmacist can help you understand whether either fits your situation.